news
MERS vaccine candidate could hold promise for COVID-19 vaccine
The vaccine candidate protected all murine models from a lethal MERS infection and could also be effective against the SARS-CoV-2 virus causing COVID-19.
List view / Grid view
Drug Development
news
EIDD-2801 shows efficacy against COVID-19 in human cells and mice
Collaborators have shown that the broad spectrum oral antiviral EIDD-2801 could be a potential prophylactic or therapeutic for COVID-19 and other coronaviruses.
article
Predicting which diabetes treatments will reach clinical trials
Researchers at MIT have developed a mathematical model that can calculate whether diabetes treatments in pre-clinical trials will be successful in humans.
news
Collaboration to develop inhaled mRNA-based antibody therapy for COVID-19
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
news
Novel COVID-19 vaccine shows efficacy in mice
Researchers have developed a vaccine against the COVID-19 coronavirus which induced the rapid production of antibodies in mice.
news
Decoy ACE2 receptors could be promising COVID-19 infection-preventing drug
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
article
How are seasonal influenza vaccines developing?
With the global ageing population at risk of death from influenza, what is pharma doing to develop more effective vaccines to combat the virus?
news
Biotech and academia collaborate on intranasal COVID-19 vaccine development
The University of Alabama at Birmingham (UAB) will run the pre-clinical trials of Altimmune’s intranasal COVID-19 vaccine candidate, AdCOVID.
news
Free access to AI Clinical Research Navigator tool for COVID-19 researchers
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.
news
Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
news
Johnson & Johnson identifies lead COVID-19 vaccine candidate
A lead COVID-19 vaccine candidate has been selected by Johnson & Johnson, after demonstrating promise in pre-clinical testing.
news
FDA and BARDA to collaborate with Grifols on COVID-19 therapeutics
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
news
Remdesivir most promising COVID-19 drug, say researchers
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
article
How labs become AI ready with advanced informatics infrastructures
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
article
Not everyone loves surprises: know your ADC’s critical quality attributes
The importance of product characterisation throughout the entire drug development process cannot be understated. Success, money and lives depend on it. This article delves into why you need to understand every aspect of an ADC in order to prevent unwelcome surprises down the line.
